"Desermisson" brush screen! The first life-saving medicine in the new crown?

June 17th, a common and inexpensive hormone drug, dexamisson, burst into flames!
A randomized controlled clinical trial at the University of Oxford in the United Kingdom found that dexamisson reduced the mortality rate of new coronal infections on ventilators by about a third, becoming the first drug to be shown to save the lives of new crown patients.
controversy ensued: the heavy use of hormone drugs during SARS left some patients with the after-effects of fem bone necrosis. Will the clinical application of dexamisson to new crown patients lead to a repeat of the tragedy?
, China Science Daily interviewed Zhan Qingyuan, director of the respiratory intensive care department at the Sino-Japanese Friendship Hospital. He is a "veteran" involved in the fight against SARS, and has been in Wuhan for months to rescue serious patients with new coronary pneumonia.
following is an exclusive interview with Zhan Qingyuan:
China Science Journal: What is your attitude towards the recent research and reporting on the drug Samisong?
: "I still have
hope for this drug, " said Zhan Qingyuan.
we have found clinically that hormone drugs do work for some new crown patients. And as the report says, more severe patients, such as those who need oxygen therapy or a ventilator, use hormone drugs better;
more important, dexamisson is a very classic old medicine, the price is also very cheap, almost every hospital has, township health can get. This is the biggest advantage of Desemisson at present.
: The hormone therapy used during SARS has left some patients with a lifetime of regret for femt bone necroticity. Was it useful for the hormone dexamisone at that time?
Qingyuan:
many kinds of glucocorticoids are used, including dexamisone. But in terms of side effects, the type of hormone is not the most important, the dose and course of treatment are the most important.
: So do you think the dexamison therapy in the British study has the potential to cause the after-effects of necrosis such as feces necrosis?
: "From the information disclosed
, I think the possibility of femtasia is not very great. According to the reported 6 mg of dexamisone, a ten-day dose and course of treatment is acceptable to people who generally do not have hormone contraindications and do not cause particularly serious long-term complications.
: When Wuhan treated many seriously ill and critically ill patients, we also accumulated a lot of experience. Why didn't you find that dexamisson had such a good effect?
: "We
also used a small amount of corticosteroids similar to those of symesone. But at the time, domestic experts disagreed on such corticosteroid drugs.
simple terms, respiratory doctors tend to find the drug effective, while doctors in intensive care often think it has limited effect and may even aggravate secondary infections.
: Why is this disagreement so great?
: Looking back now,
because the two doctors are not the same patients.
we, as respiratory doctors, see a phenomenon where these patients suddenly get worse in about 7 to 10 days. If hormones are used at this time to treat, it does prevent some patients from getting worse.
this process, the ICU's intensive care doctors can't see it. Many of the patients they took over were already extremely critical and even had multiple organ damage. At this point, the effect of corticosteroids is no longer obvious. This may lead to different doctors' different understandings of hormone therapy.
our experience is in line with the latest reports. Corticosteroids may not only reduce the death rate of patients on ventilators, but also reduce the probability of getting worse, i.e. patients who need oxygen but have not yet been on a ventilator also show improvement after medication.
: Do you have anything else to add to this study?
: The details of this
have not yet been released. In other words, we have not yet seen a peer-reviewed, officially published paper. We don't know exactly what clinical trials are designed for, or what groups of people this treatment is suitable for and what groups of people it doesn't apply to.
, the current study looked at only the short-term effects of dexamisund therapy and lacked data on long-term effects.
Nature Science Abstract:
Nature - Coronavirus Breakthrough: Dexamisson is the first drug to be shown to be life-saving
A randomized controlled clinical trial in the UK has found that a commonly priced steroid, dexamison, can save the lives of patients with COVID-19. It is the first drug to show a reduction in COVID-19 mortality. In the trial, Desamisson reduced the mortality rate of new coronavirus infections on ventilators by about a third.
the results at a June 16 press conference, and the researchers said they would publish them as soon as possible.
trial, which began in March, is one of the largest randomized controlled trials of the new coronavirus therapy in the world.
study recruited 2,100 participants and gave them a low- and medium-dose (6 mg) dose of dexamizon for ten days a day, comparing their treatment results with 4,300 people receiving standard care for new coronavirus infections.
is best for severe patients who need a ventilator. Patients who needed oxygen but had not yet been on a ventilator also showed improvement after taking the drug: the risk of death was reduced by 20 percent.
"can treat eight patients and save a life for less than 50 pounds." Martin Landray, an epidemiologist at the University of Oxford, said.
, however, dexamisson has no effect on patients with mild COVID-19 who do not absorb oxygen or use a ventilator.
the results were announced, the Uk government announced immediate approval for the use of dexamisong, which includes patients on ventilators, for COVID-19 inpatients who need oxygen.
Science - A cheap steroid that is the first drug to reduce deaths in patients with COVID-19
months after the terrible news of the spread of the new coronavirus and rising deaths around the world, there is a thy quips of hope today: researchers announced that a widely available cheap corticosteroid, dexomethason, has significantly reduced the deaths of patients with COVID-19.
the full trial data had not yet been released, some outside commentators hailed the results as a "breakthrough".
director-general of the World Health Organization (WHO), praised Thessemisson's results as "major news".
criticism that no more information had been released, Martin Landray of Oxford University, one of the lead researchers, said that since thousands of people die every day from COVID-19, it is important to send the basic message first. They hope to make all the data public in about 10 days.
if the results are confirmed, it could mean that one life would be saved for each patient treated on a ventilator.